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Abstract 
 
Introduction: An estimated 1,399 new cases of pancreatic cancer (PC) and 1,406 
deaths from the same cause occurred in Colombia in 2002. We evaluate the cost-
effectiveness of multidetector computed tomography (CT), endoscopic ultrasonography 
(EUS) and positron emission tomography with computed tomography (PET/CT) in 
diagnosis and staging of patients with clinical suspicion of PC. 
 
Materials and methods: We conducted a cost-effectiveness analysis based upon a 
systematic search to determine the strategies’ sensitivity and specificity. The costs of 
administering and monitoring were taken from the official tariff manuals. The results 
were assessed in terms of number of correct behaviours. We performed deterministic and 
probabilistic sensitivity analyses. 
 
Results: CT showed the best cost-effectiveness indicator (Col$ 3,397,163 for each 
appropriate behaviour). The cost of changing the strategy to that of CT plus EUS was 
Col$ 7,893,573 for each additional appropriate behavior. In the probabilistic analysis the 
cost-effective strategy was USE for a willingness to pay higher than Col$ 9,000,000 per 
additional unit, or TAC for smaller values.  
 
Conclusion: The cost-effective strategy in the evaluation of patients suspected PCis the 
multidetector CT. For values of willingness to pay more than Col$ 7,893,573 and Col$ 
9,000,000 per additional unit cost-effective alternatives are EUS or CT plus EUS in 
series. 
Keywords: Pancreatic neoplasms, Diagnosis, Radiology, Cost-Benefit Analysis (Source 
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1. Introduction 
Pancreatic cancer (PC) is responsible for approximately 40,000 deaths 
annually in the United States and Europe (1-2). 1,399 new cases and 1,406 
deaths from this disease were estimated for Colombia in 2002 (1). Surgery is 
currently the only curative option for these patients; however, many of them 
develop early recurrence of the disease within the first 6-12 months after 
surgery. The poor prognosis is related to the aggressive characteristics of the 
disease and the presence of extra-pancreatic tumours not found during the 
assessment prior to surgery. 
 
Multidetector CT, endoscopic ultrasonography (EUS) and more recently 
positron emission tomography over computed tomography (PET/CT) are 
used as diagnostic tools in the staging of the disease, whose objective is to 
determine tumor resectability and the metastasis detection. Assessment of 
tumor resectability has important implications for surgical management, 
because a resectable tumor undergoes surgery with curative intent, which 
has a high morbidity with no benefits in patients with unresectable or 
metastatic PC (3-5). 
 
This study aims to assess the cost-effectiveness of using CT, EUS and 
PET/CT in the diagnosis and management of patients with clinical suspicion 
of PC on the setting of the Colombian population. 
 
Methodology 
 
To evaluate the cost-effectiveness of diagnostic strategies in patients with 
suspected PC, we built a decision tree to evaluate the following strategies: 1) 
EUS, 2) multidetector CT and 3) PET/CT, 4) CT plus EUS used in series or in 
parallel (Figure 1). The model took into account the sensitivity and specificity 
indicators for cancer detection and resectability assessment for each of the 
diagnostic tests included. As a measure of effectiveness we used the number 
of appropriate treatment behaviours, considering a proper conduct when the 
diagnostic test detects the PC and adequately assesses it as resectable or 
unresectable. The time horizon was less than one year (time from initial 
evaluation until histological confirmation of resectability after surgery). No 
discount rate was applied because the time horizon was short. 
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Clinical data 
 
We conducted a systematic literature review, which extracted sensitivity and 
specificity data for detection of PC and resectability for each of the diagnostic 
tests. The PC prevalence data in patients with clinical suspicion of this 
disease, and the proportion of tumors that are resectable were obtained from 
locally conducted studies (6-12).  
 
Table 1 shows the parameters used in the model with the respective ranges 
used in sensitivity analysis. 
 
Cost data 
 
The perspective was that of the third payer, and we only included direct costs 
related to the administration of the tests, diagnostic procedures, surgical 
treatment and management of complications (Table 2). Costs were 
calculated according to the tariff rates of the official insurance handbook 
(SOAT). 
 
Economic Analysis 
 
We estimated the incremental cost-effectiveness ratios (ICER), built the 
efficiency curve, performed univariate and probabilistic sensitivity analysis 
for cost and clinical data, and calculated the acceptability curves and 
confidence regions on the effectiveness plane. 
 
Results  
 
The PET/CT strategy was more costly and less effective, taking appropriate 
behavior in only 69.2% of cases. The strategy based on CT plus EUS used in 
series to assess resectability was the most effective in taking the appropriate 
behavior for 79.7% of cases (Table 3).  
 
The strategy based on CT alone had the best cost-effectiveness ICER (Col$ 
3,397,163 for each appropriate behaviour), the cost of changing this strategy 
to CT plus EUS used in series was Col$ 7,893,573 for each additional 
appropriate behaviour gained.  
 
Figure 2 shows the efficiency frontier. The strategies with multidetector CT 
and CT plus EUS used in series fall on the curve, while that the strategies 
PET/CT, CT plus EUS used in parallel and EUS alone are dominated.  
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Sensitivity analysis  
 
Univariate analysis of costs showed that costs per hospitalization day, the 
cost of pancreaticoduodenectomy and cost of CT are the variables that affect 
the cost-effectiveness ratios. For costs per hospitalization day lower than 
Col$ 175,000, EUS becomes a cost-effective strategy; and for cost for CT 
higher than Col$ 1,270,000, the cost-effective strategy is EUS.  
 
The clinical variables affecting the cost-effectiveness ratios are: the 
specificities of CT and EUS to assess resectability, the prevalence of PC in 
patients with clinical suspicion, the sensitivity of CT for the detection of PC, 
and the proportion of PC cases resectable at diagnosis. For a specificity of the 
assessment of resectability of CT below 53% and above 70% for EUS, 
prevalence of cancer less than 76% and PC ratios resectable at diagnosis 
greater than 50%, the strategy is EUS becomes efficient and TAC plus EUS 
strategy ceases to be efficient and becomes a dominated strategy.  
 
Probabilistic sensitivity analysis  
 
We performed 10,000 Monte Carlo simulations. Figure 3 shows the 
confidence region on the plane of incremental effectiveness for CT plus EUS 
in series compared with multidetector CT. For WTP per additional unit of 
effectiveness of Col$ 7,600,000, the strategy of CT plus EUS serial is cost-
effective in 50% of the simulations (area below the diagonal), indicating that 
for this threshold there is uncertainty about whether this strategy is cost-
effective.  
 
Figure 4 shows the acceptability curves for different management strategies 
in patients with clinical suspicion of PC. For a WTP per additional 
effectiveness unit greater than or equal to Col$ 9,000,000 the cost-effective 
strategy is EUS, whereas for smaller values CT becomes cost-effective.  
 
Conclusions  
 
Assessment of resectability of pancreatic tumours at diagnosis is important 
in determining the surgical procedure with curative intent and due to the 
significant occurrence of this type of tumour in the Colombian population is 
important for the economic analysis of different diagnostic alternatives to be 
funded by the health system.  
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Several studies have demonstrated the cost-effectiveness of imaging in 
determining resectability of pancreatic tumours on imaging methods (6, 13-
14), but had not compared the three PC diagnostic imaging procedures.  
 
From the economic point of view the cost-effective strategy for assessing 
patients with clinical suspicion of PC is multidetector CT at a price for 
examination up to Col$ 583,773. Diagnosis/ staging of PC based CT plus 
EUS used in series or EUS alone to assess resectability become cost-effective 
for WTP higher than or equal to Col$ 7,893 573, and Col$ 9,000,000, 
respectively.  
 
The limitations of this study are related to the dependency of the estimates of 
cost-effectiveness on indicators that were estimated from the literature 
because, although their precise values are different for each strategy, the 
ranges overlap in some cases. In the case of the parameters of sensitivity and 
specificity of CT and PET/CT, this may result in no differences in diagnosis, 
as the probabilistic analysis could not find significant differences. 
Furthermore, the studies included in this study estimated the parameters for 
patients with symptoms of pancreatic cancer, but in Colombia the diagnosis 
is usually made in advanced stages of disease where the prognosis is more 
discouraging (12).  
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 Table 1. Parameters used in the economic evaluation of the diagnosis 
of operable pancreatic cancer. 
  Base%  Rank sensitivity analysis %   Reference  
Cancer         
PET-CT Sensitivity 84.0 68.0 100.0 (6-8) 
PET-CT Specificity  88.0 76.0 100.0 (6-8) 
TAC Sensitivity 86.0 72.0 100.0 (9-10) 
TAC Specificity  88.8 77.6 100.0 (9-10) 
EUS Sensitivity 98.0 96.0 100.0 (10-11) 
EUS Specificity  92.0 84.0 100.0 (10-11) 
Resectability        
PET-CT Sensitivity 81.0 62.0 100.0 (6-8) 
PET-CT Specificity  72.7 45.4 100.0 (6-8) 
TAC Sensitivity 92.0 84.0 100.0 (9-10) 
TAC Specificity  64.0 28.0 100.0 (9-10) 
USE Sensitivity 88.0 76.0 100.0 (10-11) 
EUS Specificity  68.0 36.0 100.0 (10-11) 
Cancer Prevalence 77 70 90 (6-11) 
Proportion of unresectable 
cancers at diagnosis 50 40 60 (6-11) 
Pancreaticoduodenectomy 
Complications        
 Risk of fistula 4.60 2.3 9.2 (12) 
Risk of abscess 3.10 1.6 6.2 (12) 
Risk of Ileus 1.50 0.8 3.0 (12) 
Hospitalization days with no 
complications after surgery  
10 8  12  Expert  
Hospitalization days after 
surgery with complications  
22  15  30  Expert  
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Table 2. Cost data used in economic evaluation  
  Base  Range sensitivity analysis 
Multidetector CT cost  Col$ 583,733  Col$ 447,467  Col$ 720,000 
Endoscopic biopsy           
                ultasonografía cost  Col$ 1,153,683  Col$ 1,069,820  Col$ 1,237,547 
PEC-TAC cost  Col$ 3,875,000  Col$ 1,937,500  Col$ 7,750,000 
Pathology study cost  Col$ 53,674  Col$ 26,837  Col$ 80,512 
Exploratory laparotomy  
               cost  Col$ 722,410  Col$ 361,205  Col$ 1,083,614 
 
Surgical treatment with  
               curative intent     
Pancreaticoduodenectomy  Col$ 1,615,050  Col$ 1,076,700  Col$ 2,153,400 
Pancreaticoduodenectomy  
               Complications     
Fistula  Col$ 1,002,946  Col$ 1,337,261  Col$ 668,631 
Abscess  Col$ 654,257  Col$ 436,171  Col$ 872,342 
Daily cost of Ileus      
               hospitalization  Col$ 205,273  Col$ 136,849  Col$ 273,697 
Surgical palliation     
Pancreatic biliary  Col$ 1,889,285  Col$ 1,259,524  Col$ 2,519,047 
Daily cost of hospitalization  Col$ 205,273  Col$ 136,849  Col$ 273,697 
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Table 3. Costs, % of appropriate behaviors, reasons of cost-
effectiveness and incremental cost-effectiveness of different strategies for 
management of patients with clinical suspicion of pancreatic cancer 
Strategies  
Cost Incremental Cost  Effectiveness  
Incremental 
effectiveness  C / E  ICER 
Multidetector CT  Col$ 
2,427,748.20   71.5%   
Col$ 
3,397,163  
EUS TAC + series  Col$ 
3,075,780.00  Col$ 648,031.80  8.2%  79.7%  
Col$ 
3,860,475  Col$ 7,893,573 
EUS  Col$ 
3,120,477.40  Col$ 44,697.40 79.6%  -0.1%  
Col$ 
3,922,563  (Dominated) 
TAC + EUS 
parallel  
Col$ 
4,243,251.50  Col$ 1,167,471.50  74.1%  -5.6%  
Col$ 
5,728,675  (Dominated) 
PET / CT  Col$ 
6,380,474.60 
Col$ 
3,304,694.60  69.2%  -10.5%  
Col$ 
9,223,538  (Dominated) 
 
Figure 1. Decision model for evaluation of the cost effectiveness of 
diagnosis of resectable pancreatic cancer. 
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Prueba positiva para cáncer
Pacientes con sospecha 
clínica de cáncer de 
páncreas
Prueba positiva para 
resecabilidad
CirugíaNo cirugía
No cirugía
SINO
SINO
 
 
 
Figure 2. Efficiency frontier on the percentage of appropriate 
behavior 
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Figure 3. Confidence regions of the probabilistic analysis of the 
comparison of CT + EUS vs series. Multidetector CT. 
 
 
 
 
 
Figure 4. Acceptability curves of different management strategies for 
patients with clinical suspicion of pancreatic cancer. 
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